Страница клинических исследований Nct
Clinical Trial Results:
A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) by intravenous administration of clazosentan, a selective endothelin A (ETA) receptor antagonist.
| Summary | |
EudraCT number | 2004-002453-31 |
Trial protocol | AT SE FI DE IT BE |
Global completion date | 30 Mar 2006 |
| Paediatric regulatory details | |
Is the trial part of an agreed EMA paediatric investigation plan? | No |
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | No |
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | No |
| Results information | |
Results version number | v1(current) |
This version publication date | 02 Dec 2016 |
First version publication date | 02 Dec 2016 |
Other versions | |
Summary report(s) | CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.